Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
Eric L. Sievers(Seagen (United States)), Irwin D. Bernstein(Fred Hutch Cancer Center), Stephen J. Forman(City Of Hope National Medical Center), Ricardo Spielberger(City of Hope), David Flowers(City Of Hope National Medical Center), M. S. Berger(City Of Hope National Medical Center), FO Smith(City Of Hope National Medical Center), F R Appelbaum(City Of Hope National Medical Center), Kathleen Shannon‐Dorcy(City Of Hope National Medical Center)
Cited by 456
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825
Antibody-Drug Conjugates in Cancer Therapy
|Annual Review of Medicine|2012|763